Nicotinamide Riboside Supplementation in Chronic Kidney Disease

Conditions

• Chronic Kidney Disease

Eligibility Criteria

Sex

ALL

Age

30 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Nicotinamide Riboside (NR) — DIETARY_SUPPLEMENT
  Nicotinamide riboside will be administered orally at a target dose of 1000 mg/day for 12 weeks during the active treatment period.
• Matched Placebo (Capsules) — DIETARY_SUPPLEMENT
  Matched placebo will be administered orally for 12 weeks during the placebo treatment period. The placebo will be identical or substantially similar in appearance to the active nicotinamide riboside study product to maintain blinding.

Study Details

This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism. The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function. Participants will be randomly assigned to one of two treatment orders. One group will take NR first and placebo second. The other group will take placebo first and NR second. Placebo looks like NR but does not contain active NR. Each treatment period lasts 12 weeks, with an approximately 2-week washout period between treatments. Neither participants nor the study team will know which treatment participants are taking during each period. Study visits will include blood and urine collection, physical function testing, and noninvasive tests of small blood vessel function. The study will enroll up to 36 adults with moderate chronic kidney disease at the University of California, San Diego.

Key Dates

First listed

Jul 9, 2026

Start date

Oct 1, 2026

Status verified

Jul 2026

Primary completion

Sep 30, 2028

Completion

Sep 30, 2028

Study Design

Enrollment

30 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Experimental: Placebo Then NR
  Participants assigned to this arm will receive matched placebo for 12 weeks, followed by an approximately 14-day washout/crossover period, then nicotinamide riboside 1000 mg/day for 12 weeks.
• Experimental: NR Then Placebo
  Participants assigned to this arm will receive nicotinamide riboside 1000 mg/day for 12 weeks, followed by an approximately 14-day washout/crossover period, then matched placebo for 12 weeks.

Primary Outcome Measure

Recruitment Rate [ Time Frame: From study opening to completion of enrollment, up to 18 months ]

Central Contacts

• Armin Ahmadi, PhD
  619-543-6248
  [email protected]

Locations (1)

Find similar trials in San Diego, CA

Related Studies

• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
  PHASE3 · Recruiting · Amgen · Los Angeles, California
• A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
  PHASE3 · Recruiting · Bayer · Phoenix, Arizona
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  PHASE3 · Recruiting · Bayer · Phoenix, Arizona
• Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial
  Enrolling By Invitation · George Washington University · San Francisco, California